Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
Public ClinicalTrials.gov record NCT07760961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Study identification
- NCT ID
- NCT07760961
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2026 (Estimated)
- Primary completion
- Oct 2027 (Estimated)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Oct 26, 2026
2026 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exalt Clinical Research | Chula Vista | California | 91910 | Recruiting |
| Stanford | Palo Alto | California | 94304 | Not yet recruiting |
| U Colorado- Anschutz Medical Campus | Aurora | Colorado | 80045 | Not yet recruiting |
| DM Clinical- Miami | Doral | Florida | 33166 | Not yet recruiting |
| Georgia Clinical Research | Lawrenceville | Georgia | 30044 | Not yet recruiting |
| Centricity Research | Morehead City | North Carolina | 28557 | Recruiting |
| Penn Medicine | Philadelphia | Pennsylvania | 19104 | Not yet recruiting |
| Vanderbilt Weight Loss Center | Nashville | Tennessee | 37204 | Not yet recruiting |
| DM Clinical- Irving | Irving | Texas | 75063 | Not yet recruiting |
| UT San Antonio | San Antonio | Texas | 78229 | Not yet recruiting |
| Texas Valley Clinical Research | Weslaco | Texas | 78596 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07760961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07760961 live on ClinicalTrials.gov.